Bank of America Corp DE increased its ADMA Biologics Inc. holdings by 107.5% during the first quarter. An August 15, 2026, SEC filing confirms the bank acquired 2.07 million additional shares. Total ownership now reaches nearly 4 million shares. This position represents approximately 1.72% of the company.
Institutional investors currently own 75.68% of the biotechnology firm. Sachem Head Capital Management and Capital Research Global Investors also recently expanded their positions.
Analysts maintain a consensus Hold rating for the company. The current price target is $18.67. ADMA Biologics met earnings per share estimates in its August 5 quarterly report.